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Attenuation of Na/K-ATPase 
Mediated Oxidant Amplification 
with pNaKtide Ameliorates 
Experimental Uremic 
Cardiomyopathy
Jiang Liu1,*, Jiang Tian2,*, Muhammad Chaudhry1, Kyle Maxwell1, Yanling Yan1, 
Xiaoliang Wang1, Preeya T. Shah1, Asad A. Khawaja1, Rebecca Martin1, Tylor J. Robinette1, 
Adee El-Hamdani1, Michael W. Dodrill1, Komal Sodhi1, Christopher A. Drummond2, 
Steven T. Haller2, David J. Kennedy2, Nader G. Abraham1,3, Zijian Xie1 & Joseph I. Shapiro1
We have previously reported that the sodium potassium adenosine triphosphatase (Na/K-ATPase) can 
effect the amplification of reactive oxygen species. In this study, we examined whether attenuation of 
oxidant stress by antagonism of Na/K-ATPase oxidant amplification might ameliorate experimental 
uremic cardiomyopathy induced by partial nephrectomy (PNx). PNx induced the development of 
cardiac morphological and biochemical changes consistent with human uremic cardiomyopathy. Both 
inhibition of Na/K-ATPase oxidant amplification with pNaKtide and induction of heme oxygenase-1 
(HO-1) with cobalt protoporphyrin (CoPP) markedly attenuated the development of phenotypical 
features of uremic cardiomyopathy. In a reversal study, administration of pNaKtide after the induction 
of uremic cardiomyopathy reversed many of the phenotypical features. Attenuation of Na/K-ATPase 
oxidant amplification may be a potential strategy for clinical therapy of this disorder.
We have shown that the plasmalemmal Na/K-ATPase has a signaling function in addition to and distinct from its 
pumping function1–3. We have also demonstrated that this signaling function may amplify oxidants and increase cel-
lular oxidant stress; conversely the blockage of this signal cascade with a designed peptide, pNaKtide, may attenuate 
oxidant stress4–7. In particular, we have recently shown that pNaKtide antagonizes the cellular generation of reactive 
oxygen species (ROS) in response to several stimuli in a dose-dependent manner both in vitro and in vivo in models 
of adipogenesis and obesity4. Alternatively, the induction of HO-1 with a variety of agents has also been shown to 
attenuate oxidant stress8–11. Patients with chronic kidney disease are at great risk for cardiovascular disease events 
and mortality and develop the clinical phenotype called “uremic cardiomyopathy”12,13. As oxidant stress is a constant 
feature of both clinical14 and experimental uremic cardiomyopathy15, we reasoned that increased detoxification of 
oxidants by HO-1 induction as well as attenuation of Na/K-ATPase signaling mediated oxidant amplification with 
pNaKtide might ameliorate the phenotypical changes in experimental uremic cardiomyopathy.
Results
Effect of telecinobufagin (TCB) and pNaKtide on collagen production and signaling in C57BL/6 
mouse primary cardiac fibroblast cells. TCB is a cardiotonic steroid. We found the TCB (100 nM, 24 h) 
induced increases in type I procollagen (procollagen-1) expression (Fig. 1A, p < 0.01 vs. control). Induction of 
HO-1 with CoPP (5 μ M, 24 h) and inhibition of Na/K-ATPase signaling with pNaKtide (1 μ M, 1 h) did not signif-
icantly affect procollagen-1 expression at baseline but significantly ameliorated TCB induced increases in procol-
lagen-1 expression (Fig. 1A, both p < 0.01 vs. TCB alone). Although TCB treatment increased HO-1 expression, 
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Figure 1. Induction of HO-1 with CoPP and blockade of Na/K-ATPase signaling with pNaKtide 
ameliorated the effect of TCB in murine cardiac fibroblasts. Primary culture of C57BL/6 mouse cardiac 
fibroblasts were used for these in vitro studies demonstrating the effects of CoPP (5 μ M, pretreated for 24 h) 
and pNaKtide (1 μ M, pretreated for 1 h) on TCB (100 nM)-induced procollagen-1 expression (A, n = 6–8), 
HO-1 expression (B, n = 6–8), c-Src activation (C, n = 6–8), ERK1/2 activation (D, n = 6–8), and protein 
carbonylation (E, n = 6). Procollagen-1 and HO-1 were determined after 24 h of TCB treatment whereas 
c-Src activation, ERK1/2 activation, and protein carbonylation were assessed after 1 h of TCB treatment. c-Src 
activation was expressed as pY418 c-Src/total c-Src (p-Src/t-Src) ratio, and ERK1/2 activation was expressed 
as phosphor-ERK/total ERK (p-ERK/t-ERK) ratio. For protein carbonylation assay, the Ponceau S stained 
membrane was used for loading control. *p < 0.05 and **p < 0.01 vs. control; $p < 0.05 and $$p < 0.01 vs. TCB 
alone.
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the effects of CoPP on HO-1 induction were considerably greater (Fig. 1B). The administration of pNaKtide had 
a small effect on HO-1 expression which did not attain statistical significance and appeared to be substantially 
less than that achieved by CoPP (Fig. 1B). TCB also induced activation of c-Src (Fig. 1C) and ERK1/2 (Fig. 1D) as 
well as oxidant stress as assessed by protein carbonylation (Fig. 1E); these measurements were also attenuated by 
pretreatment with either CoPP or pNaKtide.
Effect of pNaKtide and CoPP on PNx-mediated cardiac dysfunction and hemodynamic changes. 
As this model of experimental renal failure does not induce significant increases in blood pressure (BP) in this 
mouse strain16,17, BP measurements were reported only in the Supplementary Materials (details in Supplementary 
Materials, Table S1). Neither PNx, CoPP nor pNaKtide appeared to have substantial effects on BP in this experi-
ment. Moreover, although PNx was associated with impaired renal function, neither CoPP nor pNaKtide resulted 
in substantial changes in either plasma cystatin C, creatinine, or urea nitrogen in the setting of PNx (Supplemental 
Materials, Fig. S1).
PNx resulted in the consistent development of cardiac hypertrophy and diastolic dysfunction as assessed by 
echocardiographic methods, summarized in Table 1. Specifically, PNx increased the ventricular wall thickness 
and mass (anterior wall thickness (AWT), posterior wall thickness (PWT), relative wall thickness (RWT), and left 
ventricular mass index (LVMI)) as well as the myocardial performance index (MPI). These increases were signif-
icantly attenuated by either pNaKtide or CoPP treatment (Table 1). Neither pNaKtide nor CoPP had significant 
effects as measured by echocardiography in sham treated mice (Table 1). Interestingly, PNx induced profound 
anemia which was substantially alleviated by concomitant administration of pNaKtide, but not CoPP (Fig. 2A). 
The increase in heart weight/body weight ratio with PNx was also markedly attenuated by pNaKtide but not CoPP 
(Fig. 2B).
Effect of pNaKtide and CoPP on PNx-induced cardiac fibrosis. Administration of either pNaKtide 
or CoPP to sham surgery treated animals did not significantly affect the degree of cardiac fibrosis. PNx surgery 
was accompanied by marked degrees of cardiac fibrosis as assessed by Sirius Red/Fast Green staining (p < 0.01 vs. 
Sham alone) which was significantly attenuated by pNaKtide or CoPP treatment (Fig. 3A, both p < 0.01 vs. PNx 
alone).
In addition to the morphological changes, PNx significantly increased collagen-1 expression in left ventricle 
(LV) homogenates assayed by Western blot (Fig. 3B, p < 0.01 vs. Sham alone). Administration of either pNaKtide 
or CoPP reduced PNx-induced increases in LV collagen-1 expression (Fig. 3B, both p < 0.01 vs. PNx). While 
CoPP induced HO-1 expression most profoundly, PNx alone also induced HO-1 expression in the LV homoge-
nates (Fig. 3C, p < 0.01 vs. PNx).
At 4 weeks after PNx surgery, a significant activation of c-Src (Fig. 3D, p < 0.01 vs. Sham alone) and ERK1/2 
(Fig. 3E, p < 0.01 vs. Sham alone) was observed in LV homogenates in the PNx group that was attenuated in those 
Variable
Sham 
(n = 18) PNX (n = 21)
Sham+CoPP 
(n = 12)
PNX+CoPP 
(n = 15)
Sham+pNaktide 
(n = 13)
PNX+pNaktide 
(n = 14)
BW, g 26.4 ± 0.5 26.1 ± 0.4 28.4 ± 0.6 24.6 ± 0.6 28.1 ± 0.5 25.6 ± 0.6
HR, beat/min 429 ± 5 432 ± 18 425 ± 8 453 ± 11 442 ± 9 414 ± 10
EDA, mm2 26.3 ± 0.3 26.3 ± 0.5 28.4 ± 0.5 27.2 ± 0.6 29.6 ± 0.6 27.9 ± 0.5$
ESA, mm2 17.1 ± 0.3 17.5 ± 0.5 18.3 ± 0.5 19.0 ± 0.1 20.9 ± 0.5 20.5 ± 0.5$$
EDD, mm 4.4 ± 0.1 4.4 ± 0.4 4.5 ± 0.04 4.4 ± 0.1 4.6 ± 0.1 4.5 ± 0.5
ESD, mm 3.3 ± 0.1 3.3 ± 0.1 3.4 ± 0.1 3.2 ± 0.1 3.5 ± 0.1 3.4 ± 0.1
PWT, mm 0.59 ± 0.01 0.68 ± 0.01** 0.60 ± 0.01 0.59 ± 0.02$$ 0.62 ± 0.02 0.59 ± 0.01$$
AWT, mm 0.68 ± 0.01 0.77 ± 0.01** 0.67 ± 0.02 0.65 ± 0.01$$ 0.69 ± 0.01 0.70 ± 0.01$$
ET, msec 47 ± 0.6 46 ± 0.8 48 ± 1.0 44 ± 1.0 48 ± 0.8 48 ± 1.1
IVCT+ IVRT, (msec) 20 ± 0.5 24 ± 0.7** 19 ± 0.8 21 ± 0.7$$ 22 ± 0.8 22 ± 0.7$
PaVTI 27.52 ± 0.7 27.0 ± 0.5 30.6 ± 1.0 29.9 ± 0.5$ 28.8 ± 1.1 26.2 ± 0.7
PaD, mm 1.0 ± 0.01 1.0 ± 0.01 1.0 ± 0.02 1.0 ± 0.02 1.0 ± 0.02 1.0 ± 0.07
RWT 0.29 ± 0.01 0.33 ± 0.01** 0.28 ± 0.01 0.28 ± 0.01$$ 0.29 ± 0.01 0.29 ± 0.01$$
MPI 0.43 ± 0.01 0.51 ± 0.01** 0.40 ± 0.01 0.46 ± 0.01$$ 0.46 ± 0.02 0.46 ± 0.01$$
FS, % 25.8 ± 0.8 25.5 ± 1.1 24.7 ± 1.3 26.8. ± 1.7 24.2 ± 1.2 23.4 ± 0.9
EF, % 58.9 ± 1.3 58.1 ± 2.0 57.0 ± 2.2 60.0 ± 2.9 56.1 ± 2.1 54.8 ± 1.5
CO, ml/min 9.59 ± 0.4 9.3 ± 0.3 11.0 ± 0.6 10.5 ± 0.3 10.5 ± 0.3 8.0 ± 0.6
LVMI 3.8 ± 0.1 4.6 ± 0.1** 3.7 ± 0.1 4.0 ± 0.1$$ 4.0 ± 0.1 4.2 ± 0.1$
Table 1. Summary of transthoracic echocardiography. Values are means ± SE, BW, body weight; HR, 
heart rate; EDA, end diastolic area; ESA, end systolic area; EDD, end diastolic dimension; ESD, end systolic 
dimension; PWT, posterior wall thickness; AWT, anterior wall thickness; ET, ejection time; IVCT, isovolumic 
contraction time; IVRT, isovolumic relaxation time; PaVTI, pulmonary artery velocity time integral; PaD, 
pulmonary artery dimension; RWT, relative wall thickness; MPI, myocardial performance index; FS, fractional 
shortening; EF, ejection fraction; CO, cardiac output; LVMI, left ventricle mass index. **p < 0.01 PNx vs. Sham; 
$p < 0.05, $$p < 0.01 PNx+ CoPP or PNx+ pNaKtide vs. PNx.
www.nature.com/scientificreports/
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PNx animals treated with CoPP or pNaKtide (Fig. 3D,E, both p < 0.01 vs. PNx alone). Compared to the sham 
group, PNx stimulated protein carbonylation, an oxidative stress marker, in LV homogenates (Fig. 3F, p < 0.01 
vs. Sham alone). Administration of either CoPP or pNaKtide significantly reduced PNx-induced protein carbon-
ylation (Fig. 2F, both p < 0.01 vs. PNx alone). Lipid peroxidation data assessed by Thiobarbituric Acid Reactive 
Substances (TBARS) of LV homogenates were consistent with the carbonylation data as expected (Supplemental 
Materials, Fig. S2).
Administration of pNaKtide reversed PNx induced uremic cardiomyopathy-reversal study. In 
another set of animals, PNx was performed and mice were allowed to develop uremic cardiomyopathy for 4 
weeks. During the fifth week post PNx, pNaKtide was administered intraperitoneally at a dose of either 0, 1, 5, 10 
or 25 mg/kg body weight on day 0, day 2, and day 4, and the mice were sacrificed on day 7 of that week. Blood pres-
sure measurement and echocardiography were performed both before pNaKtide treatment and sacrifice. Again, 
BP data were not different, and we report these data in the supplement (Supplementary Materials, Table S2). 
We did note that pNaKtide appeared to reverse anemia and cardiac hypertrophy based on heart weight/body 
weight ratio, the latter in a dose dependent manner (Fig. 4A,B, respectively). In these animals, we observed that 
many (but not all) of the echocardiographic features of uremic cardiomyopathy were reversed by pNaKtide in a 
dose dependent fashion after one week (Table 2). Specifically, left ventricular wall thickness (anterior, posterior 
and relative wall thickness) as well as left ventricular mass index (LVMI) were ameliorated by pNaKtide at the 
higher doses. The myocardial performance index (MPI) changes, which were also ameliorated by pNaKtide in 
the earlier study, were not reversed by pNaKtide in this reversal study. These data are summarized in Table 2. The 
administration of pNaKtide at higher doses also reversed the fibrosis in a dose dependent manner as assessed by 
histology (Fig. 5A) and collagen-1 expression (Fig. 5B). Treatment with pNaKtide also attenuated cardiac c-Src 
activation (Fig. 5C) and ERK1/2 activation (Fig. 5D) as well as oxidant stress as assessed by protein carbonylation 
(Fig. 5E). Administration of higher doses (10 and 25 mg/kg for plasma creatinine or 25 mg/kg for BUN, respec-
tively) of pNaKtide reversed PNx-mediated increases in plasma creatinine and BUN, but not plasma cystatin C 
(Supplementary Materials, Fig. S3).
Discussion
Systemic oxidant stress is certainly part of the uremic syndrome18, and plays a critical role in the pathogenesis 
of the cardiac abnormalities seen with the syndrome called “uremic cardiomyopathy”19–21. We have previously 
demonstrated oxidant stress in experimental uremic cardiomyopathy, a phenomenon which we have attributed 
to elevated levels of cardiotonic steroids (CTS) which serve as ligands and activators for the Na/K-ATPase22,23. 
To this point, we have seen that antagonism of these CTS through active or passive immunization and through 
pharmacological strategies is effective at ameliorating physiological, morphological, and biochemical features 
of uremic cardiomyopathy in rodents24–26. On this background, we sought to examine whether blockade of 
Na/K-ATPase oxidant amplification with pNaKtide, an agent which does not affect the pumping function of the 
Na/K-ATPase, could also effectively ameliorate the phenotypical features of uremic cardiomyopathy. We used 
CoPP induction of HO-1 to examine whether this was dependent on the specific blockade of Na/K-ATPase oxi-
dant amplification or whether it was a consequence of attenuating the oxidant stress itself.
Our data clearly showed that either pNaKtide or CoPP ameliorated the physiological, morphological, and 
biochemical alterations of uremic cardiomyopathy. Specifically, the improvement of oxidant stress with either of 
these two agents resulted in improved left ventricular diastolic function and decreased hypertrophy, less cardiac 
fibrosis, and less evidence for Na/K-ATPase signaling and ROS stress. Anemia in patients with chronic kidney 
disease is associated with poor outcome, increased cardiovascular disease and mortality27. Surprisingly, amelio-
ration of the anemia associated with chronic renal failure was noted with pNaKtide but not CoPP. We expect this 
may be related to different effect durations these agents might have in different tissues, but additional work to 
understand this is critical. In the murine cardiac fibroblast system, we noted that decreasing oxidant stress with 
either pNaKtide or CoPP attenuated Na/K-ATPase signaling and collagen production to comparable degrees.
Figure 2. Effect of pNaKtide and CoPP on PNx-induced anemia and heart weight. (A) PNx induced anemia 
was substantially alleviated by administration of pNaKtide but not CoPP (n = 7− 8 per group). (B) PNx induced 
increase in heart/body weight ratio was significantly attenuated by administration of pNaKtide (n = 7− 8 per 
group). **p < 0.01, vs. Sham; $$p < 0.01 vs. PNx.
www.nature.com/scientificreports/
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Figure 3. Effect of pNaKtide and CoPP on PNx-induced cardiac fibrosis. (A) Representative images of Sirius 
Red cardiac histology (FAST Green staining as counterstaining), and data analyzed with image J and quantified 
for Sirius Red staining. For histology analysis in (A), 5 spots per section (3 sections X 5 slides per sample) were 
randomly selected and subjected to analysis using the thresholding function in Image J. (B) Representative 
western blot and data analysis of collagen-1 expression on left ventricle (LV) homogenates, n = 10 mice per 
group. (C) Representative Western blot and data analysis of HO-1 expression on LV homogenates (n = 6–8 mice 
per group). (D) c-Src activation (expressed as pY418 c-Src/total c-Src ratio) determined with western blot on 
LV homogenates (n = 10 mice per group). (E) ERK1/2 activation (expressed as phosphor-ERK/total ERK ratio) 
determined with Western blot on LV homogenates (n = 6–8 mice per group). (F) Representative Western blot 
analysis of protein carbonylation in LV homogenates with quantitative data (n = 6–8 mice per group). **p < 0.01 
vs. Sham alone; $$p < 0.01 vs. PNx alone.
www.nature.com/scientificreports/
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We further examined the effects of pNaKtide on established cardiac changes in this model. We found that 
pNaKtide reversed cardiac hypertrophy and fibrosis in a dose-dependent manner. Interestingly, changes in MPI 
with PNx, an index of systolic and diastolic function28 which were prevented by weekly administration of pNaK-
tide were not affected by the week of pNaKtide therapy in animals with established uremic cardiomyopathy at any 
dose studied. This either indicates that the functional change(s) measured with MPI are recalcitrant to reversal, or 
pNaKtide was administered for inadequate time. Again surprisingly, we found that one week of pNaKtide admin-
istration significantly improved established anemia in our model of experimental renal failure.
We believe these data are of interest for several reasons. First, it suggests a somewhat different interpretation 
of the “chicken or the egg” argument regarding oxidant stress and inflammation. While some excellent work sug-
gests that the oxidant stress in chronic kidney disease results from inflammation presumably due to various ure-
mic toxins18, our data suggest that signaling through the Na/K-ATPase may actually produce the initial oxidant 
stress which initiates recruitment of inflammation. Second and probably more importantly, our data suggest that 
therapy that allows for the attenuation of oxidant stress can ameliorate phenotypical features of uremic cardiomy-
opathy. As cardiac mortality is markedly elevated in patients afflicted with advanced renal disease29, this suggests 
the ultimate possibility of effective therapy. We note that neither HO-1 induction nor pNaKtide represent oxygen 
radical scavengers. Both strategies involve dynamic attenuation of oxidant stress by decreased production and/
Figure 4. pNaKtide reversed PNx-induced anemia and heart weight/body weight ratio. (A) PNx induced 
anemia was substantially alleviated by administration of pNaKtide (n = 7–8 per group). (B) PNx induced 
increase in heart/body weight ratio was significantly attenuated by administration of pNaKtide (n = 7–8 per 
group). *p < 0.05 and **p < 0.01, vs. Sham; $p < 0.05 vs. PNx.
Variable
PNX vehicle 
(n = 7)
PNX + 1 mg/kg 
(n = 6)
PNX + 5 mg/kg 
(n = 14)
PNX + 10 mg/kg 
(n = 14)
PNX + 25 mg/kg 
(n = 7)
BW, g 25.3 ± 1.0 26.8 ± 0.8 25.0 ± 0.8 24.1 ± 0.7 24.3 ± 0.6
HR, beat/min 432 ± 26 389 ± 6 414 ± 9 415 ± 9 392 ± 20
EDA, mm2 27.4 ± 0.4 28.0 ± 0.4 27.8 ± 0.6 27.9 ± 0.6 27.5 ± 0.5
ESA, mm2 19.4 ± 0.6 20.3 ± 0.3 20.5 ± 0.7 20.6 ± 0.5 20.0 ± 0.4
EDD, mm 4.4 ± 0.1 4.7 ± 0.03 4.6 ± 0.1 4.6 ± 0.1 4.5 ± 0.1
ESD, mm 3.4 ± 0.1 3.6 ± 0.02 3.6 ± 0.1 3.7 ± 0.1 3.6 ± 0.1
PWT, mm 0.62 ± 0.01 0.68 ± 0.02 0.59 ± 0.01$ 0.60 ± 0.01$ 0.62 ± 0.0
AWT, mm 0.81 ± 0.03 0.78 ± 0.01 0.68 ± 0.01$$ 0.64 ± 0.01$$ 0.63 ± 0.02$$
ET, msec 45 ± 1.7 48 ± 1.2 47 ± 1.0 50 ± 1.1 49 ± 2.1
IVCT+ IVRT, msec 23 ± 0.7 27 ± 0.7 24 ± 0.8 26 ± 0.7 24 ± 1.6
PaVTI 27.1 ± 0.5 26.6 ± 0.9 26.6 ± 0.8 27.2 ± 0.4 28.2 ± 0.4
PaD, mm 1.1 ± 0.02 1.0 ± 0.02 1.1 ± 0.01 1.0 ± 0.01 1.0 ± 0.02
RWT 0.33 ± 0.01 0.31 ± 0.01 0.27 ± 0.01$$ 0.27 ± 0.01$$ 0.28 ± 0.01$$
MPI 0.51 ± 0.01 0.55 ± 0.01 0.50 ± 0.01 0.52 ± 0.01 0.49 ± 0.02
FS, % 21.0 ± 1.0 22.7 ± 0.6 21.4 ± 0.8 21.1 ± 0.6 20.9 ± 1.3
EF, % 50.9 ± 2.1 53.8 ± 1.1 51.2 ± 1.5 50.7 ± 1.1 50.2 ± 2.4
CO, ml/min 10.5 ± 1.0 8.3 ± 0.2 9.7 ± 0.5 9.0 ± 0.3 8.8 ± 0.3
LVMI 4.7 ± 0.1 5.1 ± 0.1 4.5 ± 0.1 4.4 ± 0.1$ 4.3 ± 0.1$$
Table 2. Summary of transthoracic echocardiography. Values are means ± SE, BW, body weight; HR, 
heart rate; EDA, end diastolic area; ESA, end systolic area; EDD, end diastolic dimension; ESD, end systolic 
dimension; PWT, posterior wall thickness; AWT, anterior wall thickness; ET, ejection time; IVCT, isovolumic 
contraction time; IVRT, isovolumic relaxation time; PaVTI, pulmonary artery Velocity time integral; PaD, 
pulmonary artery dimension; RWT, relative wall thickness; MPI, myocardial performance index; FS, fractional 
shortening; EF, ejection fraction; CO, cardiac output; LVMI, left ventricle mass index. $p < 0.05, $$p < 0.01 vs. 
PNx-vehicle.
www.nature.com/scientificreports/
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Figure 5. Effect of pNaKtide on reversal of cardiac fibrosis following PNx. (A) Representative Sirius red images 
with quantitative data in PNx animals given vehicle or pNaKtide IP every other day beginning at 4 weeks post-PNx 
surgery or pNaKtide at 1, 5, 10 and 25 mg/kg with quantitative data (n = 6–12 mice per group). (B) Representative 
Western blots analysis of collagen-1 expression in left ventricle samples with quantitative data. (C) Representative 
phosphorylated c-Src (pY418) and total c-Src Western blots with quantitative data (n = 6–8 mice per group). (D) 
Representative phosphorylated ERK1/2 and total ERK1/2 Western blots with quantitative data (n = 6–8 mice per 
group). (E) Representative Western blot analysis of protein carbonylation in left ventricle samples with quantitative 
data (n = 6–8 mice per group) **p < 0.01 vs. Sham alone; $p < 0.05, $$p < 0.01 vs. PNx vehicle alone.
www.nature.com/scientificreports/
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or increased detoxification. As the clinical administration of reactive oxygen scavengers has been largely disap-
pointing30, this distinction is not trivial.
Materials and Methods
Experimental design. Male C57BL/6 mice (10–12 weeks old) were purchased from Hilltop Lab Animals 
Inc. (Scottsdale, PA) and housed in pathogen free animal facility in designated rooms equipped with cages that 
supply purified air under a 12-hour light/dark cycle. Food and water were supplied ad libitum. All animal care and 
experiments were approved by the Marshall University Institutional Animal Care and Use Committee (IACUC) 
of the in accordance with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory 
Animals. The number of animals in each group was determined by power analysis following assumptions derived 
from our previous study with mice22, using a variance of 0.2 within the groups, power of 0.80, and alpha error of 
0.05.
1. In vivo study I, Effects of CoPP and pNaKtide on PNx-induced uremic cardiomyopathy: Cobalt protopor-
phyrin (CoPP, Frontier Scientific, Logan, UT) was used to induce HO-1 expression and pNaKtide was used 
to block the Na/K-ATPase signaling function. The animals were randomly divided into six groups (10–12 
mice per group): (1) Sham surgery (Sham), (2) PNx surgery (PNx), (3) Sham+ CoPP (5 mg/kg BW), (4) 
PNx+ CoPP (5 mg/kg BW), (5) Sham+ pNaKtide (25 mg/kg BW), and (6) PNx+ pNaKtide (25 mg/kg BW).
2. In vivo study II, Reversal study: At week 4 of post-surgery, the animals were randomly divided into differ-
ent groups and given pNaKtide (0, 1, 5, 10 and 25 mg/kg BW) 3 times (every other day), and then sacrificed 
7 days after first injection of pNaKtide.
5/6 Nephrectomy Mouse Model. The PNx model utilized a two-step surgical approach. Step-one, instead 
of partial resection of both poles as reported elsewhere16,22, the superior and inferior poles of the left kidney 
were ligated to avoid bleeding, in a manner that approximately only 1/3 of the left kidney mass was left func-
tional. Step-two surgery was operated 7 days later, in which the right kidney was removed. For sham surgery, the 
two-step surgeries were performed in the same way as in the PNx group, without ligation of the left kidney and 
removal of right kidney. In the in vivo study I, animals were sacrificed 4 weeks after the step-two surgery. In the 
in vivo study II, animals were given either vehicle or pNaKtide beginning at 4 weeks post-surgery for one week 
and sacrificed at 5 weeks post-surgery.
Administration of pNaKtide and CoPP. In the in vivo study I, pNaKtide was dissolved in sterile PBS 
buffer and administrated (25 mg/kg BW) by intraperitoneal injection weekly, starting one week after step-two 
surgery up until the point of sacrificing. CoPP was prepared in Tris-NaOH buffer (25 mM Tris, pH 7.8–8.0) and 
administrated (5 mg/kg BW) by intraperitoneal injection. CoPP injections were given 5 days prior to, and on the 
day of, surgery, as well as every 5 days thereafter until sacrificing. In the in vivo study II, pNaKtide was adminis-
tered at 0, 1, 5, 10 and 25 mg/kg 3 times a week beginning at the end of week 4 post-surgery and sacrificed at the 
end of the additional week.
Blood Pressure (BP) measurement. Mice were first conditioned in restrainers for at least five days prior 
to the first BP reading. BP measurements were performed with CODA 8-Channel High Throughput Non-Invasive 
Blood Pressure System (Kent Scientific, Boston, MA) both one day before step-one surgery, and one day before 
sacrifice.
Transthoracic Echocardiography. Transthoracic echocardiography was performed 24 hours before sac-
rifice. Light anesthesia was achieved by continuous inhalation of isoflurane (1.5–2.5%). Mice in supine position 
were placed on a heating pad to keep the body temperature at 37 °C. Core body temperature and electrocardio-
gram (ECG) for physiological monitoring were obtained and manipulated by using VisualSonics Mouse Handling 
Table (11436) and rectal thermometer. Echocardiographic images were captured using MS400: 18–38 MHz oper-
ating frequency MicroScan transducer attached to a Vevo 1100 Imaging System (FUJIFILM VisualSonics Inc.). 
Warmed echo gel was placed between the probe and shaved chest. B-mode and M-mode images of the heart were 
obtained from parasternal long axis and short axis. Pulsed-Wave Doppler and Color Doppler were obtained from 
basal short axis. The average values were calculated from at least four consecutive cardiac cycles. Left-ventricular 
end-diastolic area (EDA), end-systolic area (ESA), as well as main pulmonary artery diameter was measured 
from B-mode. End-diastolic diameters (EDD), end-systolic diameters (ESD), as well as anterior and posterior 
wall thickness (AWT & PWT) were captured from M-mode. Isovolumic contraction and relaxation time (IVCT 
& IVRT), ejection time (ET), as well as pulmonary velocity time integral (VTI) were obtained from PW and 
color Doppler. In addition, the following parameters were calculated with the equation below: myocardial per-
formance index (MPI) = (IVCT + IVRT)/ET, relative wall thickness (RWT) = (PWT + AWT)/EDD, cardiac out-
put (CO) = stroke volume (SV) × HR/1000, fractional shortening (FS) = (EDD − ESD)/EDD, ejection fraction 
(EF) = (EDV − ESV)/EDV and the left ventricular mass index (LVMI) = 1.05[(EDD + PWT + AWT)3 − EDD3]/
Body weight (g).
Sirius Red/Fast Green staining. Histological staining for collagen fibers was perform on tissues harvested 
with Sirius Red/Fast Green Collagen Staining solutions (Sigma-Aldrich, St. Louis, MO) according to manufactur-
er’s protocol. Tissue preparation, fixation, and data analysis were conducted as previously described25.
Western Blotting Analysis. Cardiac (left ventricle, LV) tissue samples and cardiac fibroblast homogen-
ates were prepared and analyzed as we previously described for collagen-125 and other proteins5. Assessment 
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of protein carbonylation and activation of c-Src and ERK1/2 was performed as we described in ref. 5. Multiple 
exposures were analyzed to assure that the signals were within the linear range of the film. The signal density was 
determined using NIH ImageJ 1.48 v software. Polyclonal antibody against type I collagen was from Southern 
Biotech (Birmingham, AL). Polyclonal anti-Src [pY418] phospho-specific antibody was from Invitrogen 
(Camarillo, CA). Monoclonal antibody against total c-Src was from Santa Cruz (Santa Cruz, CA). Antibodies 
against phospho-ERK1/2 and total ERK1/2 were obtained from Cell Signaling Technology (Danvers, MA). 
2,4-dinitrophenylhydrazine (DNPH) and antibody against 2,4-dinitrophenyl (DNP) hydrazone derivatives were 
from Sigma-Aldrich.
Experimental design for in vitro experiment. C57BL/6 mouse primary cardiac fibroblast cells (pur-
chased from Cell Biologics, Inc., Chicago, IL) were re-suspended in complete fibroblast medium with supple-
ments and 10% FBS (Cell Biologics, Inc.). The cultures were maintained at 37 °C in a 5% CO2 incubator and the 
medium was changed after 48 h and every 2~3 days thereafter. Cardiac fibroblast cells (passage 3–4) were grown 
until over confluent and were serum-starved (with 1% FBS) overnight before being used for the experiments. 
Cells were treated with or without TCB (100 nM) to determine collagen-1 and HO-1 expression (24 h treatment), 
and c-Src and ERK1/2 activation and protein carbonylation (1 h treatment). To determine the effect of HO-1 
induction and Na/K-ATPase signaling, some cells were pre-treated with CoPP (5 μ M, 24 h) or pNaKtide (1 μ M, 
1 h) before TCB treatment.
Measurement of plasma cystatin C, creatinine and blood urea nitrogen (BUN). The Mouse cysta-
tin C ELISA kit and creatinine kit were obtained from Crystal Chem. Inc. (Downers Grove, IL). The Mouse BUN 
ELISA kit was obtained from MyBioSource Inc. (San Diego, CA). The measurements were performed following 
manufactures’ instruction. Each sample was done in duplicate.
Statistical analysis. Data were tested for normality and then subjected to parametric analysis. When more 
than two groups were compared, one-way ANOVA was performed prior to comparison of individual groups, and 
the post-hoc t-tests were adjusted for multiple comparisons using the “Holm” correction. Statistical significance 
was reported at the P < 0.05 and P < 0.01 levels. Statistical analyses were performed with the IDE RStudio for the 
R (version 3.2.5) software (from http://www.rstudio.org and https://www.R-project.org)31,32. A “pirate” plot was 
used to form graphs, in which the raw data points, full densities of each group, and Bayesian 95% Highest Density 
Intervals (HDIs) are plotted33 (please see Supplemental Materials, Fig. S5). The HDIs are calculated using the 
BEST package in R34. Values in tables are given as mean ± SEM.
Data and materials availability. All data needed to evaluate the findings in the paper are present in the 
paper and the Supplementary Materials.
Abbreviations used. Although we defined each abbreviation the first time it was mentioned in the manu-
script, we have also compiled a table (Table S3, Supplementary Materials) listing these definitions.
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